Vasculitis

Orbital Mass Presentation and Management Examined in ANCA-Associated Vasculitides

Publish Date April 10, 2019

Researchers described the presentation, therapeutic management, and outcomes of ANCA-associated vasculitides-related orbital mass.

Patient-Reported Outcome Measurement Information System Validated in Systemic Vasculitis

Publish Date March 27, 2019

Researchers assessed the feasibility and construct validity of using PROMIS instruments in systemic vasculitis.

Effects of Clinicopathologic Classification in ANCA-Associated Vasculitis

Publish Date March 15, 2019

Researchers assessed the effect of AAV reclassification based on clinicopathologic criteria and ANCA specificity.

Belimumab, Azathioprine Did Not Lower Risk for Relapse in ANCA-Associated Vasculitis

Publish Date February 13, 2019

Belimumab in combination with glucocorticoids and azathioprine did not lower the risk for relapse in patients with antineutrophil cytoplasm antibody-associated vasculitis.

Mycophenolate Mofetil Noninferior to Cyclophosphamide in ANCA-Associated Vasculitis

Publish Date February 1, 2019

Mycophenolate mofetil was noninferior to cyclophosphamide for remission induction, but resulted in higher rates of relapse.

Survival Predictors Identified in Patients With Biopsy-Proven Giant Cell Arteritis

Publish Date January 8, 2019

Researchers evaluated the influence of disease-related findings and treatment outcomes on survival in a population-based cohort of patients with giant cell arteritis.

IgA Vasculitis Associated With Increased Risk for Hypertension, Chronic Kidney Disease

Publish Date December 17, 2018

Patients with immunoglobulin A-associated vasculitis were at increased risk for hypertension and chronic kidney disease.

Vaccinations Not Linked to Childhood-Onset IgA Vasculitis

Publish Date December 10, 2018

Vaccinations most frequently administered to children did not increase the risk for IgA vasculitis onset during the 3 months post-vaccination.

Rituxan Labeling Updated With Follow-Up Treatment Info for Patients With GPA/MPA

Publish Date October 25, 2018

The FDA has approved updated labeling for Rituxan to include information on follow up treatment for patients with GPA and MPA who have achieved disease control with induction therapy.

Giant Cell Arteritis: Examining Challenges in Diagnosis and Treatment

Publish Date September 20, 2018

Improved biomarkers are needed to monitor disease activity effectively in giant cell arteritis.